Latest News

All the latest company news from Oxford Vacmedix

Professor Xiao-Ning Xu joins Scientific Advisory Council of Oxford Vacmedix

Appointment brings further expertise in immunology and pharmaceutical development to Oxford Vacmedix Oxford 12th October 2018; Oxford Vacmedix, the UK-based biopharma company focused on the development of cancer vaccines announced today that Professor Xiao-Ning Xu will join the company’s Scientific Advisory Council. Professor Xu is an immunologist who was previously a research leader at the …

Professor Xiao-Ning Xu joins Scientific Advisory Council of Oxford VacmedixRead More »

Professor Sir Andrew McMichael joins Scientific Advisory Council of Oxford Vacmedix

World-class immunologist to advise Oxford Vacmedix on development of novel cancer vaccines. Oxford Vacmedix, a UK-based biopharma company focused on the development of cancer vaccines, announced today that Professor Sir Andrew McMichael will join the company’s Scientific Advisory Council. Sir Andrew is an immunologist, Emeritus Professor, former Professor of Molecular Medicine, and previously Director of …

Professor Sir Andrew McMichael joins Scientific Advisory Council of Oxford VacmedixRead More »

Cancer vaccine firm Oxford Vacmedix confirms appointment of new Directors

Directors join Oxford Vacmedix from Myongji Hospital Group and Series A investors Cancer ROP in South Korea and Mr Jin from China. Oxford Vacmedix UK Limited (OVM), the UK-­‐based biopharma company focused on the development of cancer vaccines, confirmed today the appointment of new Directors to the Board. These new appointments follow the successful Series …

Cancer vaccine firm Oxford Vacmedix confirms appointment of new DirectorsRead More »

Cancer vaccine firm Oxford Vacmedix appoints PharmaLegacy as Contract Research Organisation

Oxford Vacmedix appoints Shanghai based PharmaLegacy to carry out the proof of concept work of both lead immunotherapy cancer vaccines, to support Phase 1 applications. Oxford Vacmedix UK Limited (OVM), the UK-based biopharma company focused on the development of cancer vaccines, announced today that PharmaLegacy of Shanghai, China has been appointed to complete the proof …

Cancer vaccine firm Oxford Vacmedix appoints PharmaLegacy as Contract Research OrganisationRead More »

Contact us

If you want to have a quick chat, or leave us some feedback,
you can contact us using any of the methods below